Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
NEJM's impact on vertebroplasty: Vertebroplasty and vertebral augmentation procedures have declined 10% since studies published in the August New England Journal of Medicine found the procedures had no lasting benefit, according to a Millennium Research Group report. The report, based on a survey of 245 U.S. physicians, said the decrease in procedures was largely due to fewer patient referrals. MRG notes that 70% of specialists who perform vertebroplasty compression fracture (VCF) treatments disagree with the NEJM findings, versus 30% of referring physicians. In the blinded, randomized, placebo-controlled studies, the treatment showed no significant difference in the primary endpoint of overall pain up to six months post-procedure (1"The Gray Sheet" Aug. 10, 2009)
You may also be interested in...
Vertebroplasty Shows No More Benefit Than Sham Procedures In Trials
The first two blinded, randomized, placebo-controlled trials of vertebroplasty treatment for spinal fractures suggest that the procedure may have no lasting benefit, researchers report in the Aug. 6 New England Journal of Medicine
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.